Merck HPV Vaccine Dual Positioning Will Target Adolescents, Older Women
Executive Summary
Merck anticipates positioning its HPV vaccine as cervical cancer prevention both for adolescents as well as "catch-up" vaccination in older women, the company told investors during its annual business review Dec. 10
You may also be interested in...
HPV Vaccine Review By CDC Cmte. Will Likely Consider Parental Choice
A review of vaccines for human papilloma virus by CDC's Advisory Committee on Immunization Practices will likely involve a discussion of societal issues surrounding the vaccination of adolescents
HPV Vaccine Review By CDC Cmte. Will Likely Consider Parental Choice
A review of vaccines for human papilloma virus by CDC's Advisory Committee on Immunization Practices will likely involve a discussion of societal issues surrounding the vaccination of adolescents
Merck HPV Vaccine BLA Filing Expected In 2005, Four Years Before GSK
Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S